Efficacy of Fumaric Acid Esters in Mouse Models of Huntington's Disease
Author Information
Author(s): Ellrichmann Gisa, Petrasch-Parwez Elisabeth, Lee De-Hyung, Reick Christiane, Arning Larissa, Saft Carsten, Gold Ralf, Linker Ralf A.
Primary Institution: Ruhr-University Bochum, Germany
Hypothesis
Does dimethylfumarate (DMF) have therapeutic efficacy in mouse models of Huntington's disease?
Conclusion
DMF treatment leads to preserved body weight, prolonged survival, and improved motor functions in mouse models of Huntington's disease.
Supporting Evidence
- DMF treatment significantly prevented weight loss in R6/2 mice.
- Average survival in the DMF group was 100.5 days compared to 94.0 days in the placebo group.
- DMF treatment resulted in a significant preservation of morphologically intact neurons in the striatum and motor cortex.
Takeaway
Researchers tested a drug called DMF on mice with Huntington's disease and found it helped them live longer and move better.
Methodology
The study used R6/2 and YAC128 transgenic mice, treated them with DMF, and assessed their weight, survival, and motor functions through various tests.
Limitations
The study design does not allow conclusions on overall loss of striatal or motor cortex neuron numbers.
Participant Demographics
Male R6/2 and YAC128 mice were used in the study.
Statistical Information
P-Value
p=0.05
Confidence Interval
DMF 97.7–104.6 vs. methocel 91.22–99.6 days
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website